Halozyme Withdraws $2.1 Billion Acquisition Bid for Evotec
Halozyme Therapeutics (NASDAQ: HALO) has pulled its proposal to buy Evotec SE (NASDAQ: EVO) for 2 billion euros ($2.09 billion) […]
Halozyme Withdraws $2.1 Billion Acquisition Bid for Evotec Read More »
